Group-Based Contingency Management for Substance Abuse Treatment - 1

Substance Abuse Clinical Trial

Official title:

Group-Based Contingency Management for Substance Abuse Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00249717
• Other study ID #: NIDA-18883-1
• Secondary ID: R01DA018883
• Status: Completed
• Phase: N/A
• First received: November 3, 2005
• Last updated: November 17, 2011
• Start date: May 2005
• Est. completion date: January 2010

Study information

• Verified date: November 2011
• Source: University of Connecticut Health Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 312
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• age > 18 years

• current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence

• willing to provide breath and urine samples for 12 weeks

• English speaking

• willing to sign informed consent

Exclusion criteria:

• serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk)

• dementia (<23 on the Mini Mental State Exam; Folstein et al. 1975)

• in recovery from pathological gambling

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Substance Abuse
• Substance-Related Disorders

Intervention

Behavioral:
• Contingency management
Receive rewards (prizes) abstinence and attendance

Locations

Country	Name	City	State
United States	University of Connecticut Health Center	Farmington	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
University of Connecticut Health Center	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug use		baseline and at each follow-up	No
Primary	Retention		each follow-up	No